Patient heterogeneity in acute myeloid leukemia - consequences for future pharmacotherapy and for the use of allogeneic stem cell transplantation
- Prosjektnummer
- 912051
- Ansvarlig person
- Øystein Bruserud
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Blood, Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Prosjektet bygger på godkjent bruk av biobankmateriale. Det er et prosjekt som bygger på laboratoriestudier og når bruken av materialet ble godkjent av etisk komite uten at brukermedvirkning var en forutsetning. Søknadene om støtte fra Kerftforeningen har heller ikke forutsatt brukermmedvirkning. Når vi informerer pasientene og får samtykke til å samle prøver til biobank innebærer dette at hver pasient får en samtale med prosjektleder som også er biobankansvarlig. Denne informasjonen inkluderer også en relativt nøye informasjon om de godkjente prosjekter for biobanken. ut over denne ene samtalem med nøye informasjon og mulighet for spørsmål har man ikke etablert brukermedvirkning.
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Cells 2019 Oct 10;8(10). Epub 2019 okt 10
PMID: 31658693
High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype.
J Clin Med 2019 Jul 04;8(7). Epub 2019 jul 4
PMID: 31277464
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.
Signal Transduct Target Ther 2019;4():20. Epub 2019 jun 19
PMID: 31240133
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.
J Cancer Res Clin Oncol 2019 Jul;145(7):1729-1749. Epub 2019 mai 20
PMID: 31111215
Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments.
Curr Med Chem 2019;26(28):5244-5261.
PMID: 30907305
A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.
Mol Cancer Ther 2019 03;18(3):567-578. Epub 2019 jan 24
PMID: 30679386
Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.
Proteomes 2018 Dec 20;7(1). Epub 2018 des 20
PMID: 30577422
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.
Biomark Res 2018;6():33. Epub 2018 nov 21
PMID: 30479769
S100 Proteins in Acute Myeloid Leukemia.
Neoplasia 2018 Dec;20(12):1175-1186. Epub 2018 okt 23
PMID: 30366122
Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.
Cancers (Basel) 2018 Sep 14;10(9). Epub 2018 sep 14
PMID: 30223538
Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.
Clin Pract 2018 Mar 28;8(2):1061. Epub 2018 jun 7
PMID: 30069300
Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Expert Opin Ther Targets 2018 07;22(7):639-653. Epub 2018 jun 22
PMID: 29889583
Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.
Expert Opin Investig Drugs 2018 Apr;27(4):377-387. Epub 2018 apr 4
PMID: 29611449
Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Int J Mol Sci 2018 Jan 27;19(2). Epub 2018 jan 27
PMID: 29382066
Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.
J Proteomics 2018 Feb 20;173():32-41. Epub 2017 nov 21
PMID: 29175091
Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.
Expert Rev Hematol 2018 01;11(1):13-24. Epub 2017 nov 23
PMID: 29168399
Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.
Int J Mol Sci 2018 Sep 22;19(10). Epub 2018 sep 22
PMID: 30249022
Immunological heterogeneity of healthy peripheral blood stem cell donors - preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation.
Expert Rev Hematol 2018 Oct;11(10):757-759. Epub 2018 aug 20
PMID: 30126308
Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood.
J Immunol Methods 2018 Oct;461():53-62. Epub 2018 jun 12
PMID: 29906454
Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.
Front Immunol 2018;9():845. Epub 2018 mai 2
PMID: 29770133
Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia.
Front Immunol 2018;9():691. Epub 2018 apr 6
PMID: 29681903
The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis.
Cytotherapy 2018 May;20(5):740-754. Epub 2018 mar 22
PMID: 29576502
A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.
Clin Exp Immunol 2018 Jul;193(1):130-141. Epub 2018 apr 1
PMID: 29513361
Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.
Int J Mol Sci 2018 Jan 19;19(1). Epub 2018 jan 19
PMID: 29351208
The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.
Int J Mol Sci 2018 Jan 15;19(1). Epub 2018 jan 15
PMID: 29342970
Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases.
Vox Sang 2018 Oct;113(7):657-668. Epub 2018 aug 29
PMID: 30159896
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
BMC Cancer 2017 Sep 06;17(1):630. Epub 2017 sep 6
PMID: 28877686
Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
Expert Opin Drug Discov 2017 Oct;12(10):1053-1065. Epub 2017 jul 27
PMID: 28748730
Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.
Expert Rev Proteomics 2017 Aug;14(8):649-663. Epub 2017 jul 27
PMID: 28693350
Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.
Front Immunol 2017;8():667. Epub 2017 jun 8
PMID: 28642760
The constitutive protease release by primary human acute myeloid leukemia cells.
J Cancer Res Clin Oncol 2017 Oct;143(10):1985-1998. Epub 2017 jun 19
PMID: 28631213
CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.
Molecules 2017 Mar 11;22(3). Epub 2017 mar 11
PMID: 28287460
Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.
Expert Opin Ther Targets 2017 Apr;21(4):357-369. Epub 2017 mar 3
PMID: 28281897
Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.
Front Immunol 2017;8():106. Epub 2017 feb 9
PMID: 28232835
Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.
Expert Rev Clin Immunol 2017 Jun;13(6):553-569. Epub 2017 jan 17
PMID: 28052713
Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Expert Opin Investig Drugs 2017 Mar;26(3):343-355. Epub 2016 des 28
PMID: 28001095
Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors.
Metabolomics 2017;13(1):2. Epub 2016 nov 28
PMID: 27980502
Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Oncotarget 2017 Jan 31;8(5):7946-7963.
PMID: 27974700
Rethinking the role of osteopontin in human acute myeloid leukemia.
Leuk Lymphoma 2017 Jun;58(6):1494-1497. Epub 2016 okt 14
PMID: 27739925
Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
Cell Death Dis 2016 Dec 01;7(12):e2497. Epub 2016 des 1
PMID: 27906185
The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Molecules 2016 Nov 11;21(11). Epub 2016 nov 11
PMID: 27845732
The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.
Metabolomics 2016;12(1):12. Epub 2015 nov 16
PMID: 27829829
Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.
Int J Mol Sci 2016 Nov 01;17(11). Epub 2016 nov 1
PMID: 27809289
Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.
Cancer Immunol Immunother 2016 Sep;65(9):1135-47. Epub 2016 aug 1
PMID: 27481108
Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.
Int J Mol Sci 2016 Jul 19;17(7). Epub 2016 jul 19
PMID: 27447610
The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.
Int J Mol Sci 2016 Jul 05;17(7). Epub 2016 jul 5
PMID: 27399678
Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients.
Biol Proced Online 2016;18():13. Epub 2016 jun 21
PMID: 27330413
A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators.
Front Immunol 2016;7():205. Epub 2016 mai 25
PMID: 27252705
Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows.
J Proteomics 2016 Aug 11;145():214-25. Epub 2016 apr 20
PMID: 27107777
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Oncotarget 2016 Feb 16;7(7):8105-18.
PMID: 26812881
Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Eur J Haematol 2016 Mar;96(3):211-21. Epub 2015 nov 26
PMID: 26465810
Nutrition in Allogeneic Stem Cell Transplantion--Clinical Guidelines and Immunobiological Aspects.
Curr Pharm Biotechnol 2016;17(1):92-104.
PMID: 26420050
The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.
Curr Pharm Biotechnol 2016;17(1):6-19.
PMID: 26343130
The PI3K-Akt-mTOR intracellular signaling pathway in human acute myeloid leukemia
- Disputert:
- mars 2019
- Hovedveileder:
- Øystein Bruserud
- Guro Kristin Melve Ph.d.-kandidat
- Sushma Bartaula Postdoktor
- Maria Hernandez-Valladares Postdoktor
- Elise Aasebø Postdoktor
- Ida Sofie Grønningsæter Ph.d.-kandidat
- Ina Nepstad Ph.d.-kandidat
- Tor Henrik Anderson Tvedt Ph.d.-kandidat
- Kristin Paulsen Rye Prosjektdeltaker
- Øystein Bruserud Prosjektleder
- Håkon Reikvam Medveileder
- Kimberley Joanne Hatfield Medveileder
- Karen Marie Hagen Prosjektdeltaker
- Annette Brenner Postdoktor
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest